XVR 012
Alternative Names: XVR-012Latest Information Update: 18 Jan 2024
At a glance
- Originator ExeVir Bio
- Class Antivirals; Single-domain antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 15 Jan 2024 Pharmacodynamics data from preclinical studies in COVID-2019 infections released by ExeVir Bio
- 28 Jun 2023 ExeVir plans a first-in-human phase Ia/Ib trial for COVID-2019 infections (Parenteral), in 2024
- 09 Jan 2023 Preclinical trials in COVID-2019 infections (Prevention) in Belgium (Parenteral)